July 16, 2025MedicinaOpen Access

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning

View Full Paper

Ask AI

Bookmark

Authors

OBOana Maria BurciuVictor Babeș University of Medicine and Pharmacy Timișoara AMAdrian-Grigore MerceVictor Babeș University of Medicine and Pharmacy Timișoara SCSimona CerbuVictor Babeș University of Medicine and Pharmacy Timișoara

Discussion

Member takes

Implication

This review evaluates endocrine therapies for breast cancer in premenopausal and postmenopausal women, highlighting hormone receptor status and recurrence risks.

Key Points

The review assesses current hormone treatment strategies for early-stage hormone receptor-positive breast cancer.
Tamoxifen is optimal for low-risk premenopausal women, showing favorable outcomes and lower toxicity.
Combination therapies, including ovarian suppression, are recommended for higher-risk premenopausal patients.
Aromatase inhibitors are standard for low-risk postmenopausal patients, with extended therapy for higher-risk cases.

Cite This Study

Burciu et al. (2025) studied this question.

synapsesocial.com/papers/689a02c9e6551bb0af8ccd28 https://doi.org/10.3390/medicina61071280

View Full Paper

Ask AI

Bookmark

Implication

This review evaluates endocrine therapies for breast cancer in premenopausal and postmenopausal women, highlighting hormone receptor status and recurrence risks.

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning

Discussion

Member takes

Implication

Key Points

Cite This Study

Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider